Latest News and Press Releases

MORRISVILLE, N.C., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today that Dr. Roger Jeffs, Chief Executive Officer, will present at the...

Liquidia will pursue final FDA approval for YUTREPIA™ (treprostinil) inhalationLiquidia will immediately request that District Court set aside injunction tied to ‘793 patent MORRISVILLE, N.C., Dec. ...

MORRISVILLE, N.C., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it has priced an underwritten public offering of 3,491,620 shares of common stock at a...

Oral arguments in appeal of ‘793 PTAB decision set for December 4, 2023PDUFA goal date to add PH-ILD indication to YUTREPIA label is January 24, 2024Hired sales force in preparation of potential...

MORRISVILLE, N.C., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its third quarter 2023 financial results on Tuesday, November 7, 2023....

Sets PDUFA goal date of January 24, 2024If approved, YUTREPIA would be indicated for treatment of both PAH and PH-ILD MORRISVILLE, N.C., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation...

Asserts ‘793 patent in new litigation filed under Hatch-Waxman Act in response to Liquidia’s amendment to its NDA to add PH-ILD to YUTREPIA™ labelLitigation is tied to same ‘793 patent previously...

MORRISVILLE, N.C., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today reported financial results for the second quarter ended June 30, 2023. The...

MORRISVILLE, N.C., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its second quarter 2023 financial results on Thursday, August 10, 2023....

No new clinical data is required to add PH-ILD indication as per FDA correspondenceRecertified that YUTREPIA does not infringe any valid patents listed in the Orange Book for TyvasoPreparing for...